TROG 16.01 (NIVORAD)
Primary sponsor: The University of Sydney
Collaborating groups: Australasian Lung Cancer Trials Group (ALTG) and Trans Tasman Radiation Oncology Group (TROG)
A randomised phase II trial of nivolumab and stereotactic ablative body radiotherapy in advanced non-small cell lung cancer, progressing after first or second line chemotherapy.
The aim of this study is to determine the activity and safety of treating an asymptomatic, extrapulmonary metastasis with a single fraction of SABR, during immunotherapy with nivolumab in advanced NSCLC progressing after 1 or 2 lines of chemotherapy.
Closed to follow up
Date of accrual completion
30th June 2019
A/Prof Paul Mitchell, Austin Health, VIC
TROG Chair: Dr Shankar Siva, Peter MacCallum Cancer Centre, VIC
NIVORAD Trial Coordinator
Phone: 02 9562 5000
TROG trial 16.01 on Australian Cancer Trials website
Trial resources for TROG members
TROG 16.01 member page